Copyright 2000 The New York Times Company
The New
York Times
View Related Topics
August 17, 2000, Thursday, Late Edition -
Final
SECTION: Section C; Page 4; Column
1; Business/Financial Desk
LENGTH: 99 words
HEADLINE: COMPANY NEWS;
SCHERING-PLOUGH GETS 6
MONTHS OF CLARITIN EXCLUSIVITY
BYLINE: Bloomberg
News
BODY:
The Schering-Plough Corporation
said yesterday that it had won an extra six months of exclusive United States
sales of its biggest product, the Claritin allergy drug, by
conducting research on how the medicine works in children. The Food and
Drug Administration rewards companies for conducting pediatric
studies by keeping generic competitors off the market for six more months. A key
Schering-Plough patent on Claritin could expire in June 2002.
With the six-month extension, the drug would face generic
competition in early 2003. Schering-Plough's shares rose $1.3125 each, to
$41.8125.
http://www.nytimes.com
LOAD-DATE: August 17, 2000 
